Anne Fortier is VP of Drug Discovery and Development at Conscience and is a seasoned drug hunter with a PhD in Biochemistry from McGill University and a track record of delivering first-in-class small-molecule therapies, including inaxaplin, through senior roles at Vertex Pharmaceuticals.